This phase 2 trial tests whether adding the immunotherapy drug durvalumab (Imfinzi) to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer live longer without their cancer growing. About 105 participants will receive either the standard t…
Phase: PHASE2 • Sponsor: Michael Hopp • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC